Eric Venker, the President & Immunovant CEO of $ROIV, sold 46,234 shares of the company on 06-24-2026 for an estimated $1,549,301. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.8% of their shares of this class of stock. Following this trade, they now own 1,613,063 shares of this class of $ROIV stock.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- FRANK TORTI (President and Vant Chair) has made 0 purchases and 3 sales selling 3,000,000 shares for an estimated $82,039,460.
- MAYUKH SUKHATME (President & CIO) has made 0 purchases and 3 sales selling 1,670,309 shares for an estimated $37,887,503.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 7 sales selling 1,200,000 shares for an estimated $33,933,267.
- KEITH S MANCHESTER has made 0 purchases and 5 sales selling 1,225,784 shares for an estimated $32,658,518.
- FINANCIAL LP QVT has made 0 purchases and 5 sales selling 1,225,784 shares for an estimated $32,658,518.
- DANIEL ALLEN GOLD has made 0 purchases and 5 sales selling 1,225,784 shares for an estimated $32,658,518.
- MATTHEW GLINE (CEO) sold 289,774 shares for an estimated $8,449,809
- MEGHAN FITZGERALD sold 70,000 shares for an estimated $1,921,500
- MELISSA B, EPPERLY sold 41,861 shares for an estimated $1,200,573
- JENNIFER HUMES (Chief Accounting Officer) sold 13,538 shares for an estimated $384,073
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ROIV Hedge Fund Activity
We have seen 258 institutional investors add shares of $ROIV stock to their portfolio, and 192 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SB INVESTMENT ADVISERS (UK) LTD removed 13,741,871 shares (-83.7%) from their portfolio in Q1 2026, for an estimated $380,649,826
- FMR LLC added 12,201,789 shares (+18.5%) to their portfolio in Q1 2026, for an estimated $337,989,555
- FARALLON CAPITAL MANAGEMENT LLC added 9,638,000 shares (+26048.6%) to their portfolio in Q1 2026, for an estimated $266,972,600
- DARWIN GLOBAL MANAGEMENT, LTD. added 6,797,300 shares (+inf%) to their portfolio in Q1 2026, for an estimated $188,285,210
- MORGAN STANLEY removed 6,531,228 shares (-11.2%) from their portfolio in Q1 2026, for an estimated $180,915,015
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,561,714 shares (+76.9%) to their portfolio in Q1 2026, for an estimated $154,059,477
- AQR CAPITAL MANAGEMENT LLC added 5,066,085 shares (+575.2%) to their portfolio in Q1 2026, for an estimated $140,330,554
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ROIV Analyst Ratings
Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 02/10/2026
To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.
$ROIV Price Targets
Multiple analysts have issued price targets for $ROIV recently. We have seen 5 analysts offer price targets for $ROIV in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Yatin Suneja from Guggenheim set a target price of $36.0 on 05/26/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $34.0 on 05/21/2026
- Yaron Werber from TD Cowen set a target price of $41.0 on 05/21/2026
- Samantha Semenkow from Citigroup set a target price of $42.0 on 05/21/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $40.0 on 04/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
